• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ETHICON INC. SFX SPI PDS+ UNI VIO 18IN 0 S/A CP-2; SUTURE, SURGICAL, ABSORBABLE, POLYDIOXANONE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ETHICON INC. SFX SPI PDS+ UNI VIO 18IN 0 S/A CP-2; SUTURE, SURGICAL, ABSORBABLE, POLYDIOXANONE Back to Search Results
Model Number SXPP1B202
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Fistula (1862); Unspecified Infection (1930); Necrosis (1971); Pocket Erosion (2013); Sepsis (2067)
Event Date 04/29/2022
Event Type  Injury  
Event Description
It was reported that a patient underwent a knee prosthesis surgery on an unknown date and a barbed suture was used.Post-op, the suture under the skin returned to the surface of the skin creating an infectious.The patient underwent scar revision with the removal of the suture.Additional information was requested.
 
Manufacturer Narrative
(b)(4).This is a combination product, and the event has been reviewed for both the suture and the triclosan.Attempts are being made to retrieve the device.To date the device has not been returned.If the device or further details are received at a later date a supplemental medwatch will be sent.Attempts are being made to obtain the following information.To date no response has been provided.If further details are received at a later date a supplemental medwatch will be sent.Please provide the patient's demographic information including age, gender, weight, bmi at the time of index procedure.Name and date of index surgical procedure? the diagnosis and indication for the index surgical procedure? what was the initial approach for the index surgical procedure? (open, laparoscopic or other)? on what tissue was the suture used? was at least one reverse stitch performed prior to closure? was the fixation loop secured to tissue at the initiation of suture use during the index procedure? what was the tissue condition (normal, thin, calcified, fragile, diseased)? did the operating surgeon observe any suture deficiency or anomaly before, during, after the suture placement or during any re-operation? please describe any medical/surgical intervention required for this suture event including dates and results.Please provide the onset date/time of the device extrusion from the initial procedure.How was the extrusion managed? please describe the patient manifestations of the reported infection (location, severity, appearance, systemic or local infection).Please provide the onset date/time of infection from the initial surgical procedure.Were there any pre-existing signs/symptoms of active infection prior to this surgical procedure? did the patient receive any prophylactic antibiotics pre-, intra- or post-operation? were cultures performed? if so, please provide the results.How much and what type of drainage is present in this wound, if applicable? other relevant patient history/concomitant medications? what is the physician¿s opinion as to the etiology of or contributing factors to this event? what is the patient's current status? are the product code and lot number the same for all 8 patients? product code sxpp1b202; lot # rbbcqt? if applicable, will product be returned? if so, please provide the return date and tracking information.Trade name - irgacare®.Active ingredient(s) ¿ triclosan.Dosage form ¿ suture/solid/parenteral.Strength ¿ = 2360 g/m.
 
Manufacturer Narrative
(b)(4).Date sent to the fda: 6/28/2022.This is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Additional information: h6 health effect - clinical codes.Additional information was requested and the following was obtained: name of index surgical procedure? total knee prosthesis on gonarthrosis.What was the initial approach for the index surgical procedure? open.On what tissue was the suture used? under skin.Was at least one reverse stitch performed prior to closure? yes.Was the fixation loop secured to tissue at the initiation of suture use during the index procedure? yes.What was the tissue condition? normal.Did the operating surgeon observe any suture deficiency or anomaly before, during, after the suture placement or during any re-operation? during the re-operation, parts of suture were found.Please describe any medical/surgical intervention required for this suture event including dates and results: recovery of the scar with removal and pose of a total knee prosthesis on (b)(6) 2022.Please provide the onset date/time of the device extrusion from the initial procedure: (b)(6) 2022.How was the extrusion managed? removal and pose of a total knee prosthesis + cleaning.Please describe the patient manifestations of the reported infection (location, severity, appearance, systemic or local infection): anteromedial subcutaneous fistulization in relation to the patellar tendon please provide the onset date/time of infection from the initial surgical procedure: deep sepsis after 5 months.Were there any pre-existing signs/symptoms of active infection prior to this surgical procedure? no.Did the patient receive any prophylactic antibiotics pre-, intra- or post-operation? céfazoline 2 gr in pre-operation.Were cultures performed? yes, on (b)(6) 2022.How much and what type of drainage is present in this wound, if applicable? no drainage.What is the physician¿s opinion as to the etiology of or contributing factors to this event? never seen skin necrosis, in 20 years of practice, in patients not subject to risk.What is the patient's current status? the patient goes well.Additional information was requested and the following was obtained: the event date in the file is listed as 12-16-2021.Is this the date of the initial procedure? yes.(b)(4).Corrected information: b3.
 
Manufacturer Narrative
(b)(4).Date sent to the fda: 6/14/2022.This is a combination product, and the event has been reviewed for both the suture and the triclosan.This report is being submitted pursuant to the provisions of 21 cfr, part 803, part 4 subpart b.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by ethicon, or its employees that the report constitutes an admission that the product, ethicon, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.A manufacturing record evaluation was performed for the finished device lot, and no non-conformances were identified.Additional information: h6.Additional information was requested and the following was obtained: product code and lot number? product code sxpp1b202; lot # rbbcqt.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SFX SPI PDS+ UNI VIO 18IN 0 S/A CP-2
Type of Device
SUTURE, SURGICAL, ABSORBABLE, POLYDIOXANONE
Manufacturer (Section D)
ETHICON INC.
1000 route 202
raritan NJ 08869
Manufacturer (Section G)
ETHICON INC.-SAN LORENZO PR
road 183, km. 8.3
san lorenzo 00754
Manufacturer Contact
elba bello
1000 route 202
raritan, NJ 08869
MDR Report Key14567587
MDR Text Key293105086
Report Number2210968-2022-04192
Device Sequence Number1
Product Code NEW
UDI-Device Identifier10705031235977
UDI-Public10705031235977
Combination Product (y/n)Y
Reporter Country CodeFR
PMA/PMN Number
NA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility,Company Representative
Reporter Occupation Other
Type of Report Initial,Followup,Followup
Report Date 06/28/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/01/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date01/31/2023
Device Model NumberSXPP1B202
Device Catalogue NumberSXPP1B202
Device Lot NumberRBBCQT
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Date Manufacturer Received06/17/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured02/12/2021
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
-
-